Search Results | Blood | American Society of Hematology

1-20 of 350

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Eno Inyang, PharmD, BCPS, Nikhil C. Munshi, MD, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 11.

DOI: https://doi.org/10.1182/blood-2020-136342

Published: 2020

Journal Articles

Monocytosis at Diagnosis Is Associated with Decreased Overall Survival in Patients with Newly Diagnosed Multiple Myeloma

Camille V Edwards, MD, Cenk Yildirim, MS, Nathanael Fillmore, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 8–9.

DOI: https://doi.org/10.1182/blood-2020-141584

Published: 2020

Journal Articles

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Blood (2020) 136 (Supplement 1): 30–31.

DOI: https://doi.org/10.1182/blood-2020-136824

Published: 2020

Journal Articles

TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

Jiye Liu, PhD, Teru Hideshima, MD PhD, Lijie Xing, MD, Su Wang, PhD, Daisuke Ogiya, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth Wen, Yu-Tzu Tai, PhD, Yong Cang, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 31.

DOI: https://doi.org/10.1182/blood-2020-139778

Published: 2020

Journal Articles

Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition

Yan Xu, MD, Yao Yao, Woojun Daniel Park, Sanika Derebail, MS, Chandraditya Chakraborty, PhD, Shidai Mu, Rafael Alonso Fernández, Srikanth Talluri, PhD, Zuzana Chyra, PhD, Kenneth Wen, Qingsheng Yan, Osasenaga Idahor, Selene Cipri, Rao Prabhala, Kenneth Anderson, MD, Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 33–34.

DOI: https://doi.org/10.1182/blood-2020-143327

Published: 2020

Journal Articles

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Abdul Hamid Bazarbachi, MD, Herve Avet-Loiseau, Zachary R Hunter, PhD, Raphael Szalat, Anil Aktas-Samur, PhD, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Mariateresa Fulciniti, PhD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Steven Treon, Mohamad Mohty, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 7–8.

DOI: https://doi.org/10.1182/blood-2020-138951

Published: 2020

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

Noopur S. Raje, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Sagar Lonial, MD FACP, Nikhil C. Munshi, MD, Philippe Moreau, MD, Hartmut Goldschmidt, MD, Michele Cavo, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Liping Huang, PhD, Amit Agarwal, MD PhD, Julie Wang, PharmD, PhD, Timothy B. Campbell, MD PhD, Jesus F. San-Miguel, MD PhD, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 37–38.

DOI: https://doi.org/10.1182/blood-2020-134319

Published: 2020

Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-141549

Published: 2020

Journal Articles

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Yao Yao, Woojun D Park, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Nicholas P Kwiatkowski, PhD, Yan Xu, MD, Chandraditya Chakraborty, PhD, Behnam Nabet, PhD, Marta Chesi, PhD, Herve Avet-Loiseau, Nathaniel Gray, Richard A. Young, PhD, Kenneth Anderson, MD, Charles Y Lin, PhD, Nikhil C. Munshi, MD, Mariateresa Fulciniti, PhD

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-142592

Published: 2020

Journal Articles

Base Excision Repair and Homologous Recombination Pathway Intermediates Drive Genomic Instability and Evolution in Myeloma

Chengcheng Liao, PhD MD, Srikanth Talluri, PhD, Subodh Kumar, PhD, Leutz Buon, Jiangning Zhao, PhD MD, Lakshmi B. Potluri, MBBS, Rao Prabhala, Masood A. Shammas, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 27–28.

DOI: https://doi.org/10.1182/blood-2020-141042

Published: 2020

Journal Articles

ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application

Subodh Kumar, PhD, Srikanth Talluri, PhD, Jiangning Zhao, PhD MD, Chengcheng Liao, PhD MD, Lakshmi B. Potluri, MBBS, Leutz Buon, Shidai Mu, Jialan Shi, MDPhD, Mychell Neptune-Buon, Chandraditya Chakraborty, PhD, Yu-Tzu Tai, PhD, Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Rao Prabhala, Masood A. Shammas, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 51.

DOI: https://doi.org/10.1182/blood-2020-142793

Published: 2020

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

DOI: https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

Chandraditya Chakraborty, PhD, Yan Xu, MD, Yao Yao, Eugenio Morelli, MD, Anil Aktas-Samur, PhD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD, Kenneth Anderson, MD, Chandraditya Chakraborty, PhD

Blood (2020) 136 (Supplement 1): 21–22.

DOI: https://doi.org/10.1182/blood-2020-142655

Published: 2020

Journal Articles

A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias

Adam S Sperling, MD PhD, Rebecca Georgakopoulou, MSc, Mehmet Kemal Samur, PhD, Christine Ivy Liacos, MSc, Brittany E Sandoval, MSc, Flora Zagouri, MD, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Despina Fotiou, BMBS, MA, Ioannis Ntanasis-Stathopoulos, MD, Evangelos Terpos, MDPhD, Efstathios Kastritis, MD, Nikhil C. Munshi, MD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 8.

DOI: https://doi.org/10.1182/blood-2020-137337

Published: 2020

Journal Articles

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 22–25.

DOI: https://doi.org/10.1182/blood-2020-136307

Published: 2020

Journal Articles

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Blood (2020) 136 (Supplement 1): 25–26.

DOI: https://doi.org/10.1182/blood-2020-140410

Published: 2020

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Yi Lin, MD PhD, Noopur S. Raje, MD, Jesus G. Berdeja, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Michaela Liedtke, MD, Jacalyn Rosenblatt, MD, Marcela V. Maus, MD PhD, Monica Massaro, MPH, Fabio Petrocca, MD, Andrea Caia, MS, Zhihong Yang, PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Nikhil C. Munshi, MD, James N. Kochenderfer, MD

Blood (2020) 136 (Supplement 1): 26–27.

DOI: https://doi.org/10.1182/blood-2020-134324

Published: 2020

Journal Articles

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Blood (2020) 136 (Supplement 1): 39.

DOI: https://doi.org/10.1182/blood-2020-134538

Published: 2020

Journal Articles

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Mehmet K. Samur, PhD, Marco Roncador, MD MSc, Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Abdul Hamid Bazarbachi, MD, Raphael Szalat, Masood A. Shammas, PhD, Adam S Sperling, MD PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Anjan Thakurta, Aurore Perrot, Jill Corre, PharmD, PhD, Philippe Moreau, MD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 4–5.

DOI: https://doi.org/10.1182/blood-2020-139014

Published: 2020

Journal Articles

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Sanika Derebail, MS, Raphael Szalat, Giovanni Parmigiani, PhD, Jill Corre, PharmD, PhD, Herve Avet-Loiseau, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 2.

DOI: https://doi.org/10.1182/blood-2020-139066

Published: 2020

2 3 4 5

NARROW

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Monocytosis at Diagnosis Is Associated with Decreased Overall Survival in Patients with Newly Diagnosed Multiple Myeloma

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Base Excision Repair and Homologous Recombination Pathway Intermediates Drive Genomic Instability and Evolution in Myeloma

ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only